Cisplatin and doxorubicin toxicosis in dogs with osteosarcoma.
Toxicosis associated with doxorubicin and cisplatin administration starting either 2 or 10 days after limb amputation for osteosarcoma was examined retrospectively in dogs. The purpose was to determine whether dosage and timing of chemotherapy affected rates of toxicosis after administration of the 1st treatment. Records of 100 dogs with appendicular osteosarcoma without evidence of metastases or concurrent disease were examined. Dogs received chemotherapy with doxorubicin and cisplatin every 3 weeks for 3 treatments starting 2 days (n = 51) or 10 days (n = 49) after amputation. The dosage of cisplatin was 60 mg/m2 and was given with 6-hour saline diuresis and butorphanol. Doxorubicin was given at 12.5-25 mg/ml during fluid administration. Hematologic data were collected before and weekly after treatment. Client interviews were conducted to assess gastrointestinal toxicosis during the interval between treatments. The reported toxicoses were graded on a scale of 0 to 4. Dogs receiving 25 mg/m2 of doxorubicin experienced greater rates of grade 4 toxicity (67%; n = 6) than dogs in groups receiving 12.5-20 mg/m2 of doxorubicin (< or = 25%; n = 94, P = .03). Dogs in the Day 2 group experienced greater rates (35%) of grade 4 toxicity than dogs in the Day 10 group (12%, P = .007). We concluded that chemotherapy administered 2 days after surgery produced an unacceptable level of toxicoses. except at greatly reduced dosages, and that even with a delay of treatment, 25 mg/m2 of doxorubicin, when given in combination with cisplatin at 60 mg/m2, was too toxic for routine use.
DeRegis
Carol J
CJ
Harrington Oncology Program, Tufts University School of Veterinary Medicine, North Grafton, MA 01536, USA.
Moore
Antony S
AS
Rand
William M
WM
Berg
John
J
D000671:Amputation, Surgical / Q000662:veterinary; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D015331:Cohort Studies; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005121:Extremities; D005260:Female; D008297:Male; D009367:Neoplasm Staging; D012516:Osteosarcoma / Q000188:drug therapy / Q000662:veterinary*; D011446:Prospective Studies; D011996:Records / Q000662:veterinary; D012189:Retrospective Studies
D004317:Doxorubicin; D002945:Cisplatin